PubMed

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD.

Diabetes Care. 2003 Aug;26(8):2370-7.PMID: 12882864 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD.

Diabetes Care. 2005 May;28(5):1083-91.PMID: 15855571 [PubMed - indexed for MEDLINE]Related articlesFree article

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.PMID: 16861088 [PubMed - indexed for MEDLINE]Related articles

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.

Diabetes Care. 2005 May;28(5):1092-100.PMID: 15855572 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME.

Clin Ther. 2007 Jan;29(1):139-53.PMID: 17379054 [PubMed - indexed for MEDLINE]Related articles

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD.

J Clin Endocrinol Metab. 2003 Jul;88(7):3082-9.PMID: 12843147 [PubMed - indexed for MEDLINE]Related articlesFree article

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

Ann Intern Med. 2008 Oct 21;149(8):531-9.PMID: 18936501 [PubMed - indexed for MEDLINE]Related articlesFree article

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M.

Diabetologia. 2007 Feb;50(2):259-67. Epub 2006 Dec 8.PMID: 17160407 [PubMed - indexed for MEDLINE]Related articles

Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

Lewin A, Lipetz R, Wu J, Schwartz S.

Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group.

Curr Med Res Opin. 2009 Jan;25(1):65-75.PMID: 19210140 [PubMed - indexed for MEDLINE]Related articles

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group.

Diabetes Care. 2004 Nov;27(11):2628-35.PMID: 15504997 [PubMed - indexed for MEDLINE]Related articlesFree article

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.

Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D.

Diabetes Technol Ther. 2005 Jun;7(3):467-77.PMID: 15929678 [PubMed - indexed for MEDLINE]Related articles

Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.

Bermúdez-Pirela VJ, Cano C, Medina MT, Souki A, Lemus MA, Leal EM, Seyfi HA, Cano R, Ciscek A, Bermúdez-Arias F, Contreras F, Israili ZH, Hernández-Hernández R, Valasco M.

Am J Ther. 2007 Mar-Apr;14(2):194-202.PMID: 17414590 [PubMed - indexed for MEDLINE]Related articles

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M.

Clin Ther. 2005 Feb;27(2):210-5.PMID: 15811484 [PubMed - indexed for MEDLINE]Related articles

Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.

Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL.

Clin Ther. 2007 Jan;29(1):74-83.PMID: 17379048 [PubMed - indexed for MEDLINE]Related articles